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radiotherapy < 0.2 ng/mL. Salvage RT was defined as radiation 
delayed until PSA rose above a threshold (≥ 0.2ng/mL). All 
patients were followed for three years. 
Results: Forty-nine patients (pre-GUROC: n = 20, post-GUROC: n 
= 29) met the inclusion criteria. Age, clinical, and pathological 
factors were similar between the two cohorts, including rates of 
ECE, SVI and post RP PSA (p > 0.05), however, there were more 
patients with positive margins in the post-GUROC cohort (50% 
versus 79%, p = 0.03). Rate of aRT offered was not significantly 
different between the pre- versus post-GUROC cohort, 65% 
versus 69%, (p > 0.05). Furthermore, no differences were noted 
between the rate of salvage RT or no RT offered between the 
cohorts: 15% versus 10% (p > 0.05), and 20% versus 21% (p > 0.05), 
respectively. 
Conclusions: Two-thirds of eligible prostate cancer patients 
referred to radiation oncologists in a particular Canadian 
province were offered aRT. This practice pattern did not 
significantly change after the publication of the GUROC 
recommendations. 
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Purpose: The standard treatment for men with newly diagnosed 
metastatic prostate cancer (mPCa) is androgen deprivation 
therapy (ADT). Local radiotherapy (RT) to the prostate has 
traditionally been reserved for men who require symptomatic 
relief in patients with metastatic disease. However, local RT may 
have other benefits in addition to symptomatic relief. This study 
investigates the impact of local RT on overall survival (OS) in men 
with newly diagnosed mPCa. 
Methods and Materials: This is a retrospective, population-based 
study of patients age > = 18 years diagnosed with metastatic (M1) 
prostate cancer in Manitoba between 2004-2013. Patients with 
neuroendocrine or small cell histology were excluded. Data was 
collected from Cancer Registry and electronic charts including 
age, T/N/M stage, PSA, Charlson comorbidity score, RT, surgery, 
systemic therapy, Gleason score, and ECOG performance status. 
Cox regression was used to predict OS. Likelihood ratio testing 
was used to identify factors associated with OS. A p value < 0.05 
was considered significant. 
Results: A total of 323 patients were included and 25 (7.7%) 
received RT to the prostate within one year of diagnosis. The 
median follow up was 2.21 years. The mean age was 71.9 years. 
Clinical T stage included T1 (9.3%), T2 (26.6%), T3 (21.7%) and 
T4 (10.5%) and TX (31.9%), N stage ranged from N0 (21.4%), N1 
(37.5%), NX (41.2%). M stages consisted of M1a/M1b (63.5%), M1c 
(14.2%) or MX (22.3%). Of the 25 patients who received prostate 
RT, 15 received high dose (≥ 50 Gy) and 10 low dose (< 50 Gy). 
Multivariable analysis showed a hazard ratio (HR) for death of 
1.09 (95% CI 0.64-1.85, p = 0.75) for patients receiving prostate 
RT (any dose) compared to those without prostate RT. 
Furthermore, the HR for high dose RT was 0.73 (95% CI 0.35-1.53, 
p = 0.41) and 1.77 (95% CI 0.89-3.52, p = 0.1) for low dose RT. 
Conclusions: In this cohort of patients with newly diagnosed 
mPCa, there was no association between RT to the prostate and 
OS. However, this study was limited by statistical power and 
additional investigation in a larger population is needed. 
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Purpose:  Dose escalation (DE) increases biochemical and local 
control in PCa. Addition of image guidance improves outcomes 
of highly conformal techniques. However, the benefit of DE and 
optimal fractionation in the context of IGRT remains unknown. 
Herein, we determine biochemical outcomes in three patient 
cohorts treated with progressively DE schemes and daily 
image-guidance (IG). 
Methods and Materials: We analyzed prospectively collected 
data from a single Institution. Departmental standard included 
three sequential prostate-only schedules, A: 75.6 Gy (1.8 Gy/d); 
B: 79.8 Gy (1.9 Gy/d); C: 78 Gy (2 Gy/d). Daily IG consisted of 
fiducial markers and daily orthogonal imaging (predominantly A 
and B) or cone beam CT (mainly C). Patients were categorized 
into NCCN risk categories, and intermediate-risk (IR) subdivided 
into favourable and unfavourable (Zumsteg’s criteria). 
Primary endpoint was biochemical recurrence (BCR) by Phoenix 
definition (PSA nadir + 2 ng/ml). Biochemical relapse-free 
rates (bRFR) were compared between three dose schedules 
and risk groups using Cox proportional hazard models and 
Kaplan-Meier method.
Results: Nine hundred and eighty-seven patients were included 
with a median age of 71.7 years. Risk category distribution was 
18% (low), 68% (IR) and 13% (high). Of IR patients (673), 62% were 
unfavourable. Two hundred and ninety-three (30%), 315 (32%) 
and 379 (38%) patients were treated with A, B and C, 
respectively. Overall, 11% of patients received ADT. Age, initial 
PSA, T-stage, Gleason score, use of ADT and risk 
category distribution were not different between three 
groups. Median follow up was 5.9 years (0.1-16.5): 9.0 years 
(0.1-16.5), 9.6 years (0.1-14.3) and 4.9 years (0.2-9.5) for A, 
B and C. bRFR was significantly different between A, B and C 
(p < 0.0001) with five year rates of 76%, 82%, 91% and eight 
year rates of 54%, 64% and 80%, respectively. Overall, 
compared to C, those treated with A and B had a HR of 2.67 
(95% CI 1.87-3.81, p < 0.001) and 1.93 (95% CI 1.34-2.77, p < 
0.001) for BCR, respectively. In low-risk category, group A 
had a higher risk of BCR compared to C (HR 4.1, 95% CI 
1.18-14.32, p = 0.027), but no difference between B and C was 
observed (p = 0.17). For favourable IR, A and B had increased 
risk of BCR (HR 4.38, 95% CI 1.68-11.4, p = 0.0025 and HR 3.05, 
95% CI 1.18-7.9, p = 0.022, respectively) compared to C. 
Findings were similar for unfavourable IR group (HR 2.24, 95% CI 
1.36-3.67, p = 0.0015 and HR 1.88, 95% CI 1.13-3.14, p = 0.015 
for A and B versus C, respectively). In high-risk category, no 
differences in BCR rates were observed.  
Conclusions:  We observed a possible continuous dose response 
and bRFR improvement with progressive DE in the context of 
daily IG, particularly significant for IR categories. With long-term 
follow up, we observed a continuous occurrence of BCR. Given 
the limitations of retrospective studies, our results justify 
further dosimetric- and technique-related factors analyses. 
Prospective validation of these findings and consideration for 
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Purpose: Recent sequencing efforts have allowed for the 
molecular taxonomy of prostate cancer (TCGA, 2015). In a sub-
set of patients, mutations and copy-number losses in the 
homologous recombination pathway were found. The TONSL-
MMS22L complex has recently been shown to be involved in the 
recovery from replication stress through homologous 
recombination (Duro et al, 2010; O'Donnell et al, 2010). It 
physically associates with BRCA1/2, RAD51, and RPA. Our study 
sought to correlate TONSL complex expression with biochemical 
relapse in prostate cancer patients 
Methods and Materials: Our cohort consists of 250 patients with 
D’Amico-classified intermediate-risk prostate cancer, treated 
with image-guided radiotherapy (IGRT, n = 116) or radical 
prostatectomy (RadP, n = 134). Pre-treatment biopsies were 
analyzed using the Affymetrix Oncoscan array. The Phoenix and 
AUA criteria was used to define biochemical relapse for RadP and 
IGRT patients respectively. mRNA expression data was taken 
from the TCGA Provisional cohort using cBioPortal (Gao et al., 
2013). 
Results: Copy number alterations of TONSL and MMS22L were 
observed in 31% (n = 78) and 20% (n = 51) of our cohort 
respectively. They were predominantly gains in TONSL, but 
losses in MMS22L. TONSL amplification, but not MMS22L, was 
significantly associated with biochemical recurrence (Chi-square 
= 12, p < 0.001). TONSL remained significantly associated on 
multivariate analysis, controlling for tumour stage, Gleason 
score, and PSA (p < 0.005). In the TCGA cohort, over-expression 
of TONSL (p < 0.005) as well as other members of the homologous 
recombination pathway (e.g. RAD51D, BRCA1, XRCC2, POLD1, 
TOP3A, etc.) were associated with disease recurrence (p < 
0.001). 
Conclusions: We identified a novel association of copy-number 
gain and over-expression of TONSL with biochemical recurrence 
following radical prostatectomy or image-guided radiotherapy. 
This points to a potential gene dosage effect and the central role 
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Purpose: Serous adenocarcinoma is a rare aggressive histologic 
subtype of endometrial cancer with a high rate of recurrence and 
a poor prognosis even at early stages. The optimal approach to 
adjuvant treatment for early stage disease is unknown. Patients 
with endometrium limited disease and a complete 
lymphadenectomy are presumed to be at lower recurrence risk. 
We report on the pathologic and treatment characteristics of 
recurrent cases in a large cohort of serous endometrial cancer 
patients to investigate whether adjuvant therapy can be omitted 
in low-risk cases. 
Methods and Materials: A retrospective chart review inclusive of 
all cases of “serous carcinoma” of the endometrium from 2000-
2014 was completed. Patients with FIGO 2009 Stage IA pure or 
mixed serous histology who had undergone total hysterectomy 
and bilateral salpingo-oophorectomy were included. Kaplan-
Meier estimates were calculated for OS and RFS and hazard ratios 
for prognostic factors were calculated using Cox proportional 
hazards modeling. 
Results: There were 63 patients with FIGO Stage 1A disease. 
Median follow up was 30.2 months. Patients were observed (n = 
33) or received adjuvant treatment (chemotherapy plus 
brachytherapy n = 21; chemotherapy alone n = 7; or pelvic 
radiotherapy +/- chemotherapy n = 2). Fifty-seven patients 
(80.2%) had pelvic lymphadenectomy (median 9 nodes). Thirty-
two patients had endometrium-confined disease. There were 
seven recurrences (11.1%), at a median of 11 months (range 8-
35). At two and five years RFS was 89.3% and 85.8%; and OS was 
92.7% and 87.6%, respectively. Of those patients observed, four 
(12.1%) developed recurrence, with two vaginal recurrences 
only. In patients with endometrium-confined disease 9% 
developed recurrence, none of whom received adjuvant therapy. 
Two of 29 patients treated with chemotherapy as a component 
of their adjuvant treatment developed recurrence (6.9%). The 
majority of patients who recurred had extrapelvic recurrence 
with or without locoregional recurrence (71.4%). More than half 
of patients who recurred did not have adequate pelvic lymph 
node assessment (four of seven cases). On multivariate analysis 
only presence of myometrial invasion (HR 1.41, p = 0.63) and 
presence of lymphovascular invasion (HR 2.69, p = 0.29) were 
associated with inferior RFS, however these were not statistically 
significant. 
Discussion: In our cohort of early stage serous endometrial 
cancers RFS and OS were inferior to those reported for patients 
with endometriod histology. Our study indicates the importance 
of adequate surgical staging in early stage disease and supports 
the use of combination chemotherapy and brachytherapy in 
adjuvant treatment, even in patients with endometrium-
confined Stage 1A disease. 
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Purpose: Surgery and post-operative adjuvant chemotherapy are 
the mainstay of treatment for patients with Stage IIIC2 
endometrial cancer. The benefit of post-operative adjuvant 
radiotherapy (RT) is not as well defined. The purpose of this 
study was to compare the patterns of failure and survival in 
patients with Stage IIIC2 endometrial cancer, treated with or 
without post-operative RT, between two provinces where 
patterns of practice differ. 
Methods and Materials: Consecutive patients diagnosed with 
FIGO Stage IIIC2 endometrial cancer from 2000-2010 were 
identified through two provincial cancer registries. 
Clinicopathologic characteristics, treatment variables (adjuvant 
chemotherapy, radiation therapy), and outcomes (patterns of 
failure, disease-free survival (DFS) and overall survival (OS) were 
analyzed. Statistical analysis was performed on STATA 14. 
Results: Fifty patients with FIGO Stage IIIC2 endometrial cancer 
were identified. Twenty-three (46%) received adjuvant RT and 
27 (54%) did not receive any adjuvant RT (RT versus NRT). Ten 
received external beam RT (EBRT) to pelvic +/- para-aortic 
lymph nodes only; one received vaginal brachytherapy only; 11 
received both (one unknown). The median age at diagnosis was 
55 for the RT group and 69 for NRT group. Grade, histology, and 
depth of myometrial invasion were similar in both groups. The 
RT group received a median of three cycles of adjuvant 
chemotherapy, while the NRT group received six cycles. Twelve 
patients (52%) in the RT group and 21 patients (78%) in the NRT 
group had disease relapse. Distant and abdominal relapse rates 
were lower in the RT versus NRT groups, (30 versus 44%, and 26 
versus 48%, respectively); pelvic/vaginal relapses (17 versus 15%) 
were similar. Median DFS was better in RT group (26.7 versus 
12.5 months, p = 0.013), while median OS was not significantly 
different (32.5 versus 29.7 months, p = 0.26). Toxicities for the 
RT group consisted of Grade 1 and 2 gastrointestinal and 
genitourinary symptoms and fatigue; Grade 3 toxicities were 
uncommon. Further data collection to increase sample size is 
ongoing. 
Conclusions: Patients with Stage IIIC2 endometrial cancer who 
received adjuvant post-operative RT following three cycles of 
